Revolution Medicines (RVMD) officer sells 3,121 shares and exercises options

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Revolution Medicines, Inc. officer Anthony Mancini reported mixed equity transactions in company common stock. He sold a total of 3,121 shares in open-market transactions at weighted average prices in the low $150s per share and exercised stock options for 3,121 shares at an exercise price of $33.62 per share.

The filing shows this activity was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 24, 2025. Following the transactions, Mancini directly holds 54,400 shares of common stock, which a footnote states includes 54,400 Restricted Stock Units, indicating these trades represent a small portion of his overall reported equity position.

Insider Trade Summary 10b5-1

Net Seller: 3,121 shares ($480,611)

Net Sell 5 txns

Insider Mancini Anthony

Role See Remarks

Sold 3,121 shs ($481K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	3,121	$0.00	--
Exercise	Common Stock	3,121	$33.62	$105K
Sale	Common Stock	700	$153.3023	$107K
Sale	Common Stock	2,000	$154.0609	$308K
Sale	Common Stock	421	$154.8157	$65K

Holdings After Transaction: Stock Option (Right to Buy) — 106,109 shares (Direct, null); Common Stock — 57,521 shares (Direct, null)

Footnotes (1)

Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on December 24, 2025. Includes 54,400 Restricted Stock Units. This transaction was executed in multiple trades at prices ranging from $152.64 to $153.48. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $153.65 to $154.51. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $154.70 to $154.95. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Twenty-five percent of the total shares subject to the option will vest on the first year anniversary measured from April 1, 2025 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Key Figures

Shares sold: 3,121 shares Sale prices: $153.30, $154.06, $154.82 per share Options exercised: 3,121 shares +5 more

8 metrics

Shares sold 3,121 shares Open-market sales of common stock on May 26, 2026

Sale prices $153.30, $154.06, $154.82 per share Weighted average prices for three reported sale blocks

Options exercised 3,121 shares Stock option exercise converting derivative rights into common stock

Option exercise price $33.62 per share Strike price for exercised stock option

Shares held after transactions 54,400 shares Direct common stock holdings, including 54,400 RSUs, after trades

Remaining option position 106,109 options Stock options reported outstanding after the derivative transaction

Option expiration March 31, 2035 Expiration date for the reported stock option grant

Vesting commencement date April 1, 2025 Start date for four-year vesting schedule of the option

Key Terms

Rule 10b5-1 trading plan, Restricted Stock Units, Stock Option (Right to Buy), exercise or conversion of derivative security, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Restricted Stock Units financial

"Includes 54,400 Restricted Stock Units."

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Stock Option (Right to Buy) financial

"security_title": "Stock Option (Right to Buy)""

exercise or conversion of derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

vesting financial

"the option will vest on each monthly anniversary of the Vesting Commencement Date"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Form 4 Insider Transactions: What Each Field Means →

05/28/2026 - 04:10 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mancini Anthony

(Last)

(First)

(Middle)

C/O REVOLUTION MEDICINES, INC.

700 SAGINAW DRIVE

(Street)

REDWOOD CITY

CALIFORNIA

94063

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Revolution Medicines, Inc. [ RVMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/26/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/26/2026		M⁽¹⁾		3,121	A	$33.62	57,521⁽²⁾	D
Common Stock	05/26/2026		S⁽¹⁾		700	D	$153.3023⁽³⁾	56,821⁽²⁾	D
Common Stock	05/26/2026		S⁽¹⁾		2,000	D	$154.0609⁽⁴⁾	54,821⁽²⁾	D
Common Stock	05/26/2026		S⁽¹⁾		421	D	$154.8157⁽⁵⁾	54,400⁽²⁾	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$33.62	05/26/2026		M⁽¹⁾			3,121	⁽⁶⁾	03/31/2035	Common Stock	3,121	$0	106,109	D

Explanation of Responses:

1. Transaction made pursuant to a 10b5-1 trading plan adopted by Anthony Mancini on December 24, 2025.

2. Includes 54,400 Restricted Stock Units.

3. This transaction was executed in multiple trades at prices ranging from $152.64 to $153.48. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

4. This transaction was executed in multiple trades at prices ranging from $153.65 to $154.51. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

5. This transaction was executed in multiple trades at prices ranging from $154.70 to $154.95. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.

6. Twenty-five percent of the total shares subject to the option will vest on the first year anniversary measured from April 1, 2025 (the "Vesting Commencement Date") and one forty-eighth (1/48th) of the shares subject to the option will vest on each monthly anniversary of the Vesting Commencement Date thereafter, so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date.

Remarks:

Chief Global Commercialization Officer

	/s/ Jack Anders, as Attorney-in-fact for Anthony Mancini	05/28/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Anthony Mancini report for Revolution Medicines (RVMD)?

Anthony Mancini reported selling 3,121 shares of Revolution Medicines common stock and exercising options for 3,121 shares. These trades occurred on May 26, 2026 and involved both open-market sales and a stock option exercise at a fixed strike price.

At what prices did Anthony Mancini sell RVMD shares in this Form 4 filing?

Mancini’s reported sales occurred at weighted average prices around $153–$155 per share. Individual transaction prices included $153.30, $154.06 and $154.82 per share, each executed in multiple trades within narrow intraday price ranges disclosed in the footnotes.

How many Revolution Medicines shares did Anthony Mancini exercise options for?

Mancini exercised stock options covering 3,121 shares of Revolution Medicines common stock. The options carried an exercise price of $33.62 per share, converting derivative rights into actual shares as part of the same day’s reported equity transactions.

How many RVMD shares does Anthony Mancini hold after these transactions?

After the reported trades, Mancini directly holds 54,400 shares of Revolution Medicines common stock. A footnote specifies this figure includes 54,400 Restricted Stock Units, meaning his reported position is largely composed of unvested or restricted equity awards rather than freely tradable shares.

Were Anthony Mancini’s RVMD stock sales under a Rule 10b5-1 plan?

Yes. A footnote states the transaction was made pursuant to a Rule 10b5-1 trading plan adopted on December 24, 2025. Such pre-arranged plans schedule trades in advance, aiming to reduce concerns about discretionary timing based on nonpublic information.

What vesting schedule applies to Anthony Mancini’s RVMD stock options?

The option vests over four years starting from April 1, 2025. Twenty-five percent vests on the first anniversary, then one-forty-eighth of the total vests monthly so that 100% of the option becomes exercisable by the fourth anniversary, contingent on continued service.